The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: A case control study

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Wang, Linbo ^a   Jiang, Zhinong ^a   Sui, Meihua ^b   Shen, Jianguo ^a   Xu, Chaoyang ^a   Fan, Weimin ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GLUTATHIONE TRANSFERASE P1; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; NAVELBINE; PROGESTERONE RECEPTOR; VINCRISTINE; ACE PROTOCOL 1; ANTINEOPLASTIC AGENT; COF PROTOCOL; DOXORUBICIN; ETOPOSIDE; FEC PROTOCOL; STEROID; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENETIC MARKER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PREOPERATIVE TREATMENT; PRIMARY TUMOR; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT RESPONSE; BREAST TUMOR; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; RECEPTORS, PROGESTERONE; STEROIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE;

EID: 68349101166     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-226     Document Type: Article

References (51)

1. Gralow JR Burstein HJ Wood W Hortobagyi GN Gianni L von Minckwitz G Buzdar AU Smith IE Symmans WF Singh B Winer EP Preoperative therapy in invasive breast cancer: Pathologic assessment and systemic therapy issues in operable disease J Clin Oncol 2008, 26:814-819 10.1200/ JCO.2007.15.3510 18258991
2. Buzdar AU Preoperative chemotherapy treatment of breast cancer-a review Cancer 2007, 110:2394-2407 10.1002/cncr.23083 17941030
3. Subramaniam DS Isaacs C Utilizing prognostic and predictive factors in breast cancer Curr Treat Options Oncol 2005, 6:147-159 10.1007/ s11864-005-0022-1 15717996
4. Schmid P Wischnewsky MB Sezer O Böhm R Possinger K Prediction of response to hormonal treatment in metastatic breast cancer Oncology 2002, 63:309-316 10.1159/000066224 12417785
5. Horwitz KB McGuire WL Predicting response to endocrine therapy in human breast cancer: A hypothesis Science 1975, 189:726-727 10.1126/ science.168640 168640
6. Low SC Dixon AR Bell J Ellis IO Elston CW Robertson JF Blamey RW Tumour oestrogen receptor content allows selection of elderly patients with breast cancer for conservative tamoxifen treatment Br J Surg 1992, 79:1314-1316 10.1002/bjs.1800791224 1486427
7. Van Poznak C Tan L Panageas KS Arroyo CD Hudis C Norton L Seidman AD Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer J Clin Oncol 2002, 20:2319-2326 10.1200/JCO.2002.08.125 11981003
8. Faneyte IF Schrama JG Peterse JL Remijnse PL Rodenhuis S Vijver van de MJ Breast cancer response to neoadjuvant chemotherapy: Predictive markers and relation with outcome Br J Cancer 2003, 88:406-412 10.1038/ sj.bjc.6600749 12569384
9. Chhieng DC Rodriguez-Burford C Meleth S Grizzle WE Ferguson SM Assessment of biomarker expression in predicting pathologic response to neoadjuvant chemotherapy in patients with locally advanced breast cancer Breast J 2007, 13:534-535 10.1111/j.1524-4741.2007.00483.x 17760684
10. Bottini A Berruti A Bersiga A Brizzi MP Brunelli A Gorzegno G DiMarco B Aguggini S Bolsi G Cirillo F Filippini L Betri E Bertoli G Alquati P Dogliotti L p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients Clin Cancer Res 2000, 6:2751-2758 10914720
11. Makris A Powles TJ Dowsett M Osborne CK Trott PA Fernando IN Ashley SE Ormerod MG Titley JC Gregory RK Allred DC Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas Clin Cancer Res 1997, 3:593-600 9815725
12. Kuerer HM Newman LA Smith TL Ames FC Hunt KK Dhingra K Theriault RL Singh G Binkley SM Sneige N Buchholz TA Ross MI McNeese MD Buzdar AU Hortobagyi GN Singletary SE Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 1999, 17:460-469 10080586
13. Tomczykowski J Szubstarski F Kurylcio L Stanislawek A Barycki J Baranowski W Does the degree of cell lesion in breast cancer after inductive chemotherapy have any prognostic value? Acta Oncol 1999, 38:949-953 10.1080/028418699432644 10606425
14. Katzenellenbogen BS Mechanisms of action and cross-talk between estrogen receptor and progesterone receptor pathways J Soc Gynecol Investig 2000, 7(1 Suppl):S33-37 10.1016/S1071-5576(99)00058-1 10732327
15. Mano MS Rosa DD De Azambuja E Ismael GF Durbecq V The 17q12-q21 amplification: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours Cancer Treat Rev 2007, 33:64-77 10.1016/ j.ctrv.2006.10.001 17113234
16. Volm M Multidrug resistance and its reversal Anticancer Res 1998, 18(4C):2905-2917 9713485
17. Sataloff DM Mason BA Prestipino AJ Seinige UL Lieber CP Baloch Z Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: A determinant of outcome J Am Coll Surg 1995, 180:297-306 7874340
18. Sui M Chen F Chen Z Fan W Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors Int J Cancer 2006, 119:712-717 10.1002/ijc.21743 16496381
19. Kang SP Martel M Harris LN Triple negative breast cancer: Current understanding of biology and treatment options Curr Opin Obstet Gynecol 2008, 20:40-46 10.1097/GCO.0b013e3282f40de9 18197004
20. Chintamani Singh JP Mittal MK Saxena S Bansal A Bhatia A Kulshreshtha P Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer-a prospective clinical study World J Surg Oncol 2005, 3:61 1224882 16164742 10.1186/1477-7819-3-61
21. Kiang DT Frenning DH Goldman AI Ascensao VF Kennedy BJ Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer N Engl J Med 1978, 299:1330-1334 714108
22. Colleoni M Minchella I Mazzarol G Nolè F Peruzzotti G Rocca A Viale G Orlando L Ferretti G Curigliano G Veronesi P Intra M Goldhirsch A Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors Ann Oncol 2000, 11:1057-1059 10.1023/A:1008334404825 11038046
23. Berry DA Cirrincione C Henderson IC Citron ML Budman DR Goldstein LJ Martino S Perez EA Muss HB Norton L Hudis C Winer EP Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer JAMA 2006, 295(14):1658-1667 1459540 16609087 10.1001/jama.295.14.1658
24. MacGrogan G Mauriac L Durand M Bonichon F Trojani M de Mascarel I Coindre JM Primary chemotherapy in breast invasive carcinoma: Predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi Br J Cancer 1996, 74:1458-1465 8912545
25. Stearns V Singh B Tsangaris T Crawford JG Novielli A Ellis MJ Isaacs C Pennanen M Tibery C Farhad A Slack R Hayes DF A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer Clin Cancer Res 2003, 9(1):124-133 12538460
26. Lippman ME Allegra JC Thompson EB Simon R Barlock A Green L Huff KK Do HM Aitken SC Warren R The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer N Engl J Med 1978, 298:1223-1228 651963
27. Sui M Huang Y Park BH Davidson NE Fan W Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death Cancer Res 2007, 67:5337-5344 10.1158/ 0008-5472.CAN-06-4582 17545614
28. Gapinski PV Donegan WL Estrogen receptors and breast cancer: Prognostic and therapeutic implications Surgery 1980, 88:386-393 7414516
29. Hilf R Feldstein ML Gibson SL Savlov ED The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer Cancer 1980, 45:1993-2000 10.1002/ 1097-0142(19800415)45:8<1993::AID-CNCR2820450802>3.0.CO;2-2 7370949
30. Hilf R Feldstein ML Savlov ED Gibson SL Seneca B The lack of relationship between estrogen receptor status and response to chemotherapy Cancer 1980, 46(12 Suppl):2797-2800 10.1002/ 1097-0142(19801215)46:12+<2797::AID-CNCR2820461411>3.0.CO;2-B 7448724
31. Minisini AM Di Loreto C Mansutti M Artico D Pizzolitto S Piga A Puglisi F Topoisomerase IIalpha and APE/ref-1 are associated with pathologic response to primary anthracycline-based chemotherapy for breast cancer Cancer Lett 2005, 224(1):133-139 15911109
32. Graham JD Clarke CL Physiological action of progesterone in target tissues Endocr Rev 1997, 18:502-519 10.1210/er.18.4.502 9267762
33. Bouchard P Progesterone and the progesterone receptor J Reprod Med 1999, 44(2 Suppl):153-157 11392025
34. Ross JS Fletcher JA Bloom KJ Linette GP Stec J Symmans WF Pusztai L Hortobagyi GN Targeted therapy in breast cancer: The HER2/neu gene and protein Mol Cell Proteomics 2004, 3:379-398 10.1074/mcp.R400001-MCP200 14762215
35. Traina A Agostara B Marasà L Calabrò M Zarcone M Carruba G HER2/neu expression in relation to clinicopathologic features of breast cancer patients Ann N Y Acad Sci 2006, 1089:159-167 10.1196/ annals.1386.029 17261764
36. Tiezzi DG Andrade JM Ribeiro-Silva A Zola FE Marana HR Tiezzi MG HER2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination BMC Cancer 2007, 7:36 1820790 17324279 10.1186/1471-2407-7-36
37. Rody A Karn T Gätje R Ahr A Solbach C Kourtis K Munnes M Loibl S Kissler S Ruckhäberle E Holtrich U von Minckwitz G Kaufmann M Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response Breast 2007, 16:86-93 10.1016/ j.breast.2006.06.008 17010609
38. Warm M Kates R Mallmann P Dick M Nawroth F Harbeck N Paepke S Thomas A Impact of tumor biological factors on response to pre-operative epirubicin and paclitaxel chemotherapy in primary breast cancer Anticancer Res 2007, 27:1031-1038 17465239
39. Pegram MD Finn RS Arzoo K Beryt M Pietras RJ Slamon DJ The effect of HER2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells Oncogene 1997, 15:537-547 10.1038/ sj.onc.1201222 9247307
40. Liedtke C Mazouni C Hess KR André F Tordai A Mejia JA Symmans WF Gonzalez-Angulo AM Hennessy B Green M Cristofanilli M Hortobagyi GN Pusztai L Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 2008, 26:1275-1281 10.1200/JCO.2007.14.4147 18250347
41. Keam B Im SA Kim HJ Oh DY Kim JH Lee SH Chie EK Han W Kim DW Moon WK Kim TY Park IA Noh DY Heo DS Ha SW Bang YJ Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: Paradoxical features of the triple negative breast cancer BMC Cancer 2007, 7:203 2217558 17976237 10.1186/1471-2407-7-203
42. Carey LA Dees EC Sawyer L Gatti L Moore DT Collichio F Ollila DW Sartor CI Graham ML Perou CM The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 2007, 13:2329-2334 10.1158/1078-0432.CCR-06-1109 17438091
43. Gurbuxani S Zhou D Simonin G Raina V Arya LS Sazawal S Marie JP Bhargava M Expression of genes implicated in multidrug resistance in acute lymphoblastic leukemia in India Ann Hematol 1998, 76:195-200 10.1007/ s002770050388 9671132
44. Galimberti S Testi R Guerrini F Fazzi R Petrini M The clinical relevance of the expression of several multidrug-resistant-related genes in patients with primary acute myeloid leukemia J Chemother 2003, 15:374-379 12962366
45. Chintamani Singh JP Mittal MK Saxena S Bansal A Bhatia A Kulshreshtha P Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer-a prospective clinical study World J Surg Oncol 2005, 3:61 1224882 16164742 10.1186/1477-7819-3-61
46. Koh EH Chung HC Lee KB Lim HY Kim JH Roh JK Min JS Lee KS Kim BS The value of immunohistochemical detection of P-glycoprotein in breast cancer before and after induction chemotherapy Yonsei Med J 1992, 33:137-142 1357834
47. Seymour L Bezwoda WR Dansey RD P-glycoprotein immunostaining correlates with ER and with high Ki67 expression but fails to predict anthracycline resistance in patients with advanced breast cancer Breast Cancer Res Treat 1995, 36:61-69 10.1007/BF00690186 7579508
48. MacGrogan G Rudolph P Mascarel Id I Mauriac L Durand M Avril A Dilhuydy JM Robert J Mathoulin-Pélissier S Picot V Floquet A Sierankowski G Coindre JM DNA topoisomerase IIalpha expression and the response to primary chemotherapy in breast cancer Br J Cancer 2003, 89:666-671 10.1038/sj.bjc.6601185 12915875
49. Durbecq V Paesmans M Cardoso F Desmedt C Di Leo A Chan S Friedrichs K Pinter T Van Belle S Murray E Bodrogi I Walpole E Lesperance B Korec S Crown J Simmonds P Perren TJ Leroy JY Rouas G Sotiriou C Piccart M Larsimont D Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel Mol Cancer Ther 2004, 3:1207-1214 15486187
50. Cardoso F Durbecq V Larsimont D Paesmans M Leroy JY Rouas G Sotiriou C Renard N Richard V Piccart MJ Di Leo A Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/ metastatic breast cancer Int J Oncol 2004, 24:201-209 14654958
51. Villman K Sjöström J Heikkilä R Hultborn R Malmström P Bengtsson NO Söderberg M Saksela E Blomqvist C TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer Acta Oncol 2006, 45:590-596 10.1080/02841860500543182 16864174